

On page 28 at line 21, after "CC(AG)ATGGGNACCAGCCA(CT)TC" and before the "." please insert --(SEQ ID NO:11)--.

On page 29 at line 1, after "(GTAGTCTAGAGAACTGATTCCGCAGCCTTCCAA)" and before the word please insert --(SEQ ID NO:19)--.

On page 29 at line 3, after "(GTAGTCTAGATCATGGAGGTCGGGTACAAGC)" please insert --(SEQ ID NO:20)--.

On page 29 at line 4, after "(GTAGTCTAGATCAAGCTTGGCACATAAAACCTC)" please insert --(SEQ ID NO:21)--.

On page 29 at line 7, after "(GTAGTCTAGACAAGCTTGTCGACCAGGTTTC)" and before the word "and" please insert --(SEQ ID NO:22)--.

On page 29 at line 10, after "AGAG)" and before the "." please insert: --(SEQ ID NO:23).

On page 30 at line 3, after "GTAGTCTAGACAGGACCCGGGCTCCAAGGC" and before the word "was" please insert --(SEQ ID NO:24)--.

On page 30 at line 4, after "(QDPGSKA)" and before the word "of" please insert --(SEQ ID NO:25)--.

**IN THE CLAIMS:**

**Please cancel Claims 13-19, and 25-33**

**Please amend the remaining claims as follows:**

1. (Amended) [A]An isolated ligand-binding domain of an Eph family RTK.
2. (Amended) [A]The isolated ligand-binding domain according to Claim 1, wherein the Eph-family RTK is [HEK]an EphA3 RTK.
3. (Amended) [A]The isolated ligand-binding domain according to Claim 1, [which] wherein said domain is capable of binding LERK7.
4. (Amended) [A]An isolated ligand-binding domain of an Eph-family RTK which has at least one disulphide bond involving cysteine residues corresponding to conserved cysteine residues in HEK [which] wherein said disulphide-bonded cysteines are selected from the group consisting of:-
  - (i) Cys<sub>71</sub>-Cys<sub>189</sub>;
  - (ii) Cys<sub>257</sub>-Cys<sub>270</sub>;
  - (iii) Cys<sub>259</sub>-Cys<sub>270</sub>;

(iv) Cys<sub>306</sub>-Cys<sub>322</sub>; and

(v) Cys<sub>362</sub>-Cys<sub>365</sub>;

5. (Amended) [A]An isolated ligand-binding domain of an Eph-family RTK [which has] comprising an amino acid sequence encoded by exon III of a gene encoding an Eph family RTK.

6. (Amended) [A]The isolated ligand binding domain according to Claim 5, wherein the ligand-binding domain further [includes]comprises an amino acid sequence encoded by exon II of said gene.

7. (Amended) [A]The isolated ligand-binding domain [of an Eph family RTK which has] according to Claim 6, wherein said ligand-binding domain further comprises an amino acid sequence encoded by exon I[, exon II and exon III] of said gene.

8. (Twice Amended) [A]The isolated ligand-binding domain [of an Eph family RTK which has amino acids 52-271 of the sequence of SEQ ID NO:2]according to Claim 7, wherein exon I has a nucleotide sequence according to SEQ ID NO:6.

9. (Twice Amended) [A]An isolated ligand-binding domain of an Eph family RTK [which further includes one or more of amino acids 30-51 of the sequence of SEQ ID NO:2]comprising an amino acid sequence encoded by a nucleotide sequence according to SEQ ID NO:5.

10. (Twice Amended) [A]An isolated ligand-binding domain of an Eph family RTK [which has amino acids 1-271 of the sequence of SEQ ID NO:2]comprising an amino acid sequence according to SEQ ID NO:1.

11. (Amended) An isolated [poly]peptide [homolog of]comprising a sub-sequence of a ligand-binding domain of an Eph family RTK.

12. (Amended) [A]An isolated polypeptide homolog of a ligand-binding domain of an Eph family RTK [corresponding to a sub-sequence of an amino acid sequence according to Claim 10].

20. (Twice Amended) A recombinant polypeptide produced by [the]a host cell [of Claim 18]wherein said recombinant polypeptide comprises said ligand-binding domain of Claim

1. 21. (Amended) A method of identifying a molecule which binds an Eph family RTK, which method includes the steps of:-

(i) combining a sample suspected of containing said molecule [and]with at least [a]the isolated ligand-binding domain of said Eph family RTK of Claim 1; and

(ii) determining if said molecule is present in said sample by measuring binding of the molecule to the ligand-binding domain.

22. A method of identifying a molecule which competes with binding of a ligand to a ligand-binding domain of an Eph family RTK, which method includes the steps of:-

(i) combining a sample suspected of containing the molecule, a ligand and at least the ligand-binding domain of said Eph family RTK of Claim 1; and

(ii) determining if the molecule is present in the sample according to whether the molecule competes with the ligand for binding to the ligand-binding domain.

24. A method according to Claim 22, wherein the Eph family RTK is HEK.

**Please add the following claims:**

3435. The isolated ligand-binding domain according to Claim 1, wherein the EphA3 RTK is HEK.

3536. An isolated ligand-binding domain according to Claim 5, wherein exon III has a nucleotide sequence according to SEQ ID NO:8.

3637. An isolated ligand-binding domain according to Claim 6, wherein exon II has a nucleotide sequence according to SEQ ID NO:7.

3738. The isolated ligand-binding domain according to Claim 5, wherein said ligand-binding domain further comprises an amino acid sequence encoded by exon I of said gene.

3839. The isolated ligand-binding domain according to Claim 38, wherein exon I has a nucleotide sequence according to SEQ ID NO:6.

3940. An isolated ligand-binding domain according to Claim 10, which further comprises an amino acid sequence according to SEQ ID NO:2.

4041. An isolated ligand-binding domain according to Claim 10 or Claim 40, which further comprises an amino acid sequence according to SEQ ID NO:3.

4142. An isolated recombinant Eph-family RTK ligand-binding domain comprising the amino acid sequence of SEQ ID NO:4.

4243. A method according to Claim 21, wherein the Eph family RTK is HEK.

**IN THE SEQUENCE LISTING:**

Please insert the Sequence Listing pages 1-11.